Deeptech VCs are still too risk-averse with spinouts, and it’s costing them, say Europe’s leading spinout investors

I spend a lot of time talking to founders who are trying to drag technology out of the lab and into the real world. In Europe, this usually means dealing with the university spinout machine. On paper, it looks like a goldmine. You have some of the brightest minds in quantum, biotech, and materials science sitting on IP that could change the world. But there is a massive disconnect between the scientists building the tech and the VCs who are supposed to fund it.

The consensus among the people actually doing the work—the specialized spinout investors who live in the trenches—is that mainstream deeptech VCs are still too scared of their own shadows. They are treating fundamental scientific breakthroughs with the same risk-mitigation playbook they use for B2B software companies. And frankly, it is not working.

The Valuation Trap

Most generalist VCs look at a university spinout and see a mess. They see a cap table cluttered with university ownership, a founding team that has never managed a P&L, and a product that might not have a market for ten years. Because of these perceived risks, they try to crush the valuation or demand terms that effectively kill the founders' motivation before the first prototype is even built.

This is a founder-first problem. If you are a builder in this space, you know that the early days are not about scaling; they are about proving the physics. Traditional VCs want to see "traction," a word that has become almost meaningless in deeptech. You cannot show month-over-month recurring revenue when you are still trying to figure out if your fusion reactor stays stable for more than a millisecond.

The investors who actually win in this space know that risk in a spinout is not about the market—it is about the technical milestone. If the science works, the market will eventually show up. But VCs are so used to the low-capital, high-speed world of SaaS that they lack the patience for the hard stuff.

The Expertise Gap

One of the biggest issues I see is that many VCs claiming to do "deeptech" don't actually have anyone on staff who understands the science. They rely on external consultants or, worse, they just look at who else is in the round. This herd mentality is the opposite of what builders need. It leads to a situation where great tech gets ignored because it does not fit a neat category, while mediocre tech gets funded because it sounds like something else that recently exited.

Specialized spinout investors have a different edge. They understand the nuances of tech transfer offices. They know how to navigate the bureaucratic nightmare of university IP negotiations. More importantly, they aren't afraid of the "valley of death"—that gap between a government grant and a Series A. Mainstream VCs wait for the gap to be bridged; spinout investors help build the bridge.

Why Founders are Frustrated

For a founder, the current landscape feels like an uphill battle. You are expected to be a world-class researcher and a slick Silicon Valley CEO at the same time. When VCs complain that spinout founders are "too academic," they are missing the point. You want the person who spent a decade mastering the science to lead the vision. You can hire a COO to handle the spreadsheets later.

• Cap Table Health: Universities in Europe often take too much equity, leaving too little for the founders and future investors.
• Time Horizons: Fund cycles are usually 10 years, which is often too short for true deeptech breakthroughs.
• Technical Diligence: Most investors cannot tell the difference between a marginal improvement and a paradigm shift.

These factors create a friction that slows down innovation. We have the talent and the research, but we are choking it with a lack of courage from the money side.

A Change in Perspective

What needs to happen? First, we need to stop pretending that every startup is a software company. The metrics for success in deeptech are different. We need to value milestones like patent filings, successful lab trials, and hardware prototypes as much as we value seat licenses.

Second, builders need to be more selective about who they let onto their cap table. If an investor asks you for a three-year revenue forecast when you are still in the R&D phase, they aren't the right partner. They will panic the moment a technical hurdle appears, and in deeptech, hurdles are the only guarantee.

The biggest risk in deeptech isn't that the technology fails; it's that the investors lose their nerve before the technology has a chance to succeed.

The investors who are currently cleaning up in the spinout space are the ones who aren't afraid to get their hands dirty. They are helping founders recruit the right commercial talent and helping them talk to the university bureaucrats. They aren't just writing checks; they are acting as a buffer between the lab and the harsh realities of the market.

The Takeaway for Builders

If you are spinning out a company, don't just chase the biggest name in VC. Look for the investors who have a track record of sticking through the hard years. The "risk-averse" label currently being slapped on European deeptech VCs is a warning sign. It means the capital is available, but it comes with strings that might pull your company apart.

We need more conviction. The next decade won't be defined by another social media app or a slightly faster way to deliver groceries. It will be defined by the people solving energy, health, and computation at a fundamental level. If VCs can't handle the risk of the lab, they shouldn't be in the room.

Build for the long term, protect your equity from greedy institutions, and find the investors who actually understand the math. The gap between the lab and the market is where the real value is created, but only if you have the stomach to cross it.

Read the original at Sifted →